FDA approves Boehringer's lung disease drug
The U.S. Food and Drug Administration on Friday approved German drugmaker Boehringer Ingelheim's Ofev capsules for a rare lung disorder. The drug is first FDA-approved treatment for this condition, the FDA said in a statement. The drug is aimed at slowing the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis, an autoimmune condition. Ofev was originally approved in 2014 for adult patients with idiopathic pulmonary fibrosis, which is another interstitial lung condition.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
